louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02345096: Effect of Saccharomyces Cerevisiae on Improving the Effectiveness of Conventional Treatment of Vulvo-vaginal Candidiasis
Official title: A Randomized, Double-blind, Placebo Controlled Study to Evaluate the Effect of Saccharomyces Cerevisiae on Improving the Effectiveness of Conventional Treatment of Vulvo-vaginal Candidiasis
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Vulvo-vaginal Candidiasis
Lead sponsor: Lesaffre International
Sponsor class: INDUSTRY
Collaborators: name: Eurofins Optimed
First posted: 2015-01-26
Enrollment: 22
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This study aims to evaluate the effect of a specific strain of Saccharomyces cerevisiae on improving the effectiveness of conventional treatment of vulvo-vaginal candidiasis. This is a randomized, double-blind, placebo-controlled study.


Eligibility criteria: Inclusion Criteria:

* Premenopausal female patient with a clinical diagnosed vulvo-vaginal candidiasis
* Regularly menstruating women with normal gynaecological status
* Patient must use a contraception method
* Having given a written informed consent prior to selection
* Covered by Health Insurance System and / or in compliance with the recommendations of National Law in force relating to biomedical research.

Exclusion Criteria:

* Pregnancy or breast feeding.
* Tumors in the genital tract or beast.
* Hypersensitivity to the study product.
* Uterine or vaginal bleeding of unknown origin.
* Use of systemic or intravaginal antibiotic or antifungal agents in the previous 14 days.
* Concomitant medication with antimycotics for other diagnoses.
* Woman with known transmitted infections such as Neisseria gonorrhoea, Chlamydia trachomatis, Treponema pallidum, herpes simplex, Trichomonas vaginalis, human papilloma virus, HIV 1 or 2.
* Immunocompromised individuals.
* Subjects not willing to stop taking probiotics in the form of dietary supplements or convenient goods
* Subject who, in the judgment of the Investigator, is likely to be non-compliant or uncooperative during the study, or unable to cooperate because of a language problem, poor mental development.
* Subject under administrative or legal supervision.
* Subject who participate to a previous study within 3 months.

Primary outcomes:
measure: Enumeration of Candida albicans in a vaginal sampling
timeFrame: up to 2 months
Secondary outcomes:
Other outcomes:
Locations:
city: Gières
country: France
facility: Eurofins Optimed
Study officials:
affiliation: Independant gynecologist
name: Robert Cherbut, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00383396: Efficacy of Topical Cyclosporine 0.05% in the Prevention of Ocular Surface Inflammation Secondary to Pterygia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Pterygia
Lead sponsor: Innovative Medical
Sponsor class: INDUSTRY
First posted: 2006-10-03
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP

Brief summary: To Determine if topical cyclosporine 0.05% BID prevents recurrent inflammation and improves comfort in eyes with pterygia.


Eligibility criteria: Inclusion Criteria:

* pts with symptomatic pterygia unresponsive to palliative treatment.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Boynton Beach
country: United States
facility: Dr. Schechter
state: Florida
Study officials:
affiliation: Florida Eye Microsurgical Institute
name: Barry Schechter, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03793296: Percutaneous Device Closure for Significant Paravalvular Leakage After Transcatheter or Surgical Valve Replacement
Official title: Percutaneous Device Closure for Significant Paravalvular Leakage After Transcatheter or Surgical Valve replacement_Pilot Study
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Cardiac Valves
Heart Valve Diseases
Valvular Insufficiency
Keywords: Paravalvular leak
Lead sponsor: Asan Medical Center
Sponsor class: OTHER
Collaborators: name: CardioVascular Research Foundation, Korea
First posted: 2019-01-04
Enrollment: 0
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study evaluates the effectiveness and safety of Percutaneous Device Closure for Significant Paravalvular Leakage after transcatheter or surgical valve replacement.


Eligibility criteria: Inclusion Criteria:

* Significant Paravalvular Leakage After Transcatheter or Surgical Valve Replacement
* Required treatment of paravalvular leakage due to heart failure or hemolysis
* There is a formal agreement of heart team as following

  * predicted high-risk (STS score ≥8 OR Logistic EuroSCORE ≥20% OR operative mortality is ≥15%)
* Inoperable status due to old age or frailty
* Written consent

Exclusion Criteria:

* Risk of valve embolization because of valve dehiscence or instability
* Acute myocardial ischemia (enzyme elevation, ST elevation on EKG(electrocardiogram), or chest pain/discomfort)
* Evidence of intracardiac mass, thrombus or vegetation on Transthoracic/Transesophageal echocardiographic study
* Life expectancy less than 6 months due to non-cardiac disease
* Pregnant or breastfeeding

Primary outcomes:
measure: Degree of para-valvular leakage
timeFrame: 1 month
Secondary outcomes:
measure: Event rate of all cause death
timeFrame: up to 5 years
measure: Event rate of cardiac death
timeFrame: up to 5 years
measure: Event rate of stroke
timeFrame: up to 5 years
measure: Event rate of myocardial infarction
timeFrame: up to 5 years
measure: Event rate of rehospitalization
timeFrame: up to 5 years
measure: Event rate of infection
timeFrame: up to 5 years
measure: Event rate of acute kidney injury
timeFrame: 1 month
measure: Event rate of vascular complication
timeFrame: 1 month
measure: Event rate of bleeding
timeFrame: 1 month
measure: Event rate of device success
timeFrame: 1 month
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Asan Medical Center
Study officials:
References:
Clinical trial NCT01255696: Safety and Efficacy of Varying Methods of ALV003 Administration for the Treatment of Celiac Disease
Official title: A Phase 2a, Double-Blind, Placebo Controlled Study of the Efficacy, Safety and Tolerability of 6-weeks Treatment With Varying Methods of ALV003 Administration in Patients With Well-Controlled Celiac Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Celiac Disease
Keywords: Celiac Disease
Coeliac Disease
Celiac Sprue
Keliakia Disease
Lead sponsor: Alvine Pharmaceuticals Inc.
Sponsor class: INDUSTRY
First posted: 2010-12-07
Enrollment: 61
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A phase 2a study to evaluate the safety and efficacy of ALV003 to treat celiac disease.


Eligibility criteria: Inclusion Criteria:

* History of biopsy-proven celiac disease
* Adherence to a gluten-free diet
* TG2 antibody negative
* Signed informed consent

Exclusion Criteria:

* Active dermatitis herpetiformis
* History of IgE-mediated reactions to gluten
* Use of specific medications 6 months prior to entry
* History of alcohol abuse or illicit drug use
* Current untreated or GI disease
* Positive pregnancy test
* Received any experimental drug within 14 days of randomization
* Uncontrolled chronic disease or condition
* Uncontrolled complications of celiac disease
* Any medical condition which could adversely affect study participation

Primary outcomes:
measure: Efficacy: Intestinal mucosal morphology
timeFrame: 6 weeks
measure: Safety: Tolerability of ALV003
timeFrame: 6 weeks
Secondary outcomes:
measure: Efficacy: Change in intestinal intraepithelial lymphocyte numbers/phenotype
timeFrame: 6 weeks
measure: Efficacy: Change in serological markers of celiac disease
timeFrame: 6 weeks
Other outcomes:
Locations:
city: Kuopio
country: Finland
facility: Terveystalo Kuopio
city: Oulu
country: Finland
facility: Oulu Diakonissalaitos (ODL)
city: Tampere
country: Finland
facility: FINN-MEDI Research Oy - Clinical Trials Center
Study officials:
affiliation: FINN-MEDI Research Oy
name: Marja-Leena Lähdeaho, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Tampere University
name: Markku Mäki, MD, PhD
role: STUDY_CHAIR
References:
citation: Lahdeaho ML, Kaukinen K, Laurila K, Vuotikka P, Koivurova OP, Karja-Lahdensuu T, Marcantonio A, Adelman DC, Maki M. Glutenase ALV003 attenuates gluten-induced mucosal injury in patients with celiac disease. Gastroenterology. 2014 Jun;146(7):1649-58. doi: 10.1053/j.gastro.2014.02.031. Epub 2014 Feb 25.
Clinical trial NCT05030896: Ultrasound-guided Percutaneous Electrolysis in Female Soccer With Soleus Injury
Official title: Clinical Application of Percutaneous Electrolysis in Female Soccer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Injury;Sports
Lead sponsor: University of Seville
Sponsor class: OTHER
First posted: 2021-09-01
Enrollment: 20
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study evaluates if the physiotherapy treatment based on combination of therapeutic exercise program and ultrasound-guided PNE on chronic soleous injuries may cause changes in pain, dorsal flexion of the ankle and muscle fatigue in female dance


Eligibility criteria: Inclusion Criteria:

* older than 18 years
* having a soleus muscle injury
* chronic injury (\> 3 meses)
* pain at stretch \> 3 points measured by NRS

Exclusion Criteria:

* belenophobia
* other accuse injury
* lumbar back pathology

Primary outcomes:
measure: Pain at palpation
timeFrame: From baseline measurement up to one month
measure: Pain at stretch
timeFrame: From baseline measurement up to one month
Secondary outcomes:
measure: ankle dorsiflexion
timeFrame: From baseline measurement up to one month
measure: muscle fatigue
timeFrame: From baseline measurement up to one month
Other outcomes:
Locations:
city: Seville
country: Spain
facility: University of Seville
Study officials:
References:
Clinical trial NCT01090596: Changes in mRNA Expression Following Exposure to Naproxen
Official title: Changes in mRNA Expression Following Exposure to Naproxen
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Lead sponsor: Research Associates of New York, LLP
Sponsor class: OTHER
First posted: 2010-03-22
Enrollment: 48
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: Using tissue samples obtained from a previous study, the effect of naproxen on the gene expression profiles of antral mucosal tissue will be assessed. We hypothesize that there will be distinct changes in the gene expression profiles of samples taken from individuals treated with naproxen versus samples taken from individuals treated with placebo.

Detailed description: We will use microarray technology to quantify the transcriptome-wide changes in gene expression in said-samples.

Eligibility criteria: Inclusion Criteria:

* Healthy adult between the ages of 18 and 75 inclusive
* Written informed consent prior to undergoing any study procedures
* A physical examination which reveals no clinically significant abnormalities
* Female subjects of childbearing potential must be taking an acceptable form of contraceptive

Exclusion Criteria:

* Any mucosal breaks within 2 cm of pyloric channel seen on baseline endoscopy
* Any GDU or \>5 gastroduodenal erosions at baseline endoscopy
* CXB, CPG, ASA, or NS-NSAID use within the prior 2 weeks
* Previous gastrointestinal ulcer
* Hypersensitivity or allergy to NSAIDs, ASA, CPG, CXB or other contraindication to taking treatments
* Baseline complaints of abdominal pain, nausea, and/or cramping
* Any acid blocking medication including antacids, H-2 receptor blocker within the prior 2 weeks, or PPI use within the prior 30 days
* Corticosteroids use within the prior 60 days
* Any documented bleeding tendency
* Has taken warfarin within the prior 60 days
* Three or greater alcoholic beverages daily
* History of cerebro-vascular event

Primary outcomes:
measure: Fold Change in Gene Expression
timeFrame: 7 days
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Research Associates of New York
name: James Aisenberg, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04781296: Spectral CT With Advanced CT Technology
Official title: Spectral Computed Tomography With Photon-counting Detector
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: CT Photon-Counting
Lead sponsor: GE Healthcare
Sponsor class: INDUSTRY
Collaborators: name: Prismatic Sensors AB
First posted: 2021-03-04
Enrollment: 27
Sex: MALE
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: The single group model will enroll subjects from 5 anatomical areas (lungs, brain/carotid vessels, heart/chest, MSK and abdomen) where CT imaging is applicable and where data on the photon-counting CT is needed to assess feasibility and guide further development of the technology.
Primary purpose: DEVICE_FEASIBILITY

Brief summary: The purpose of the study is to collect data to evaluate feasibility of the using photon-counting CT in a clinical setting.

Detailed description: Data collected in this study includes an assessment of image quality parameters including spatial resolution, image contrast, and noise that will evaluate the product and how this photon-counting CT technology can be used to reduce the overall radiation dose in CT imaging, and enhance clinical applications for CT technology.

Eligibility criteria: Inclusion Criteria:

* Age \>50 years
* Male
* Normal renal function per standardized guidelines (GFR \> 60 mL/min)
* Previous CT examination at KS no more than 12 months prior to the study examination
* Signed informed consent

Exclusion Criteria:

* Iodine contrast is contraindicated.

Primary outcomes:
measure: Evaluate feasibility of the photon-counting CT in a clinical setting.
timeFrame: 1 year
Secondary outcomes:
measure: Collect feedback on performance and images generated on the photon-counting CT.
timeFrame: 1 year
Other outcomes:
Locations:
city: Stockholm
country: Sweden
facility: Karolinska University Hospital
Study officials:
affiliation: GE Healthcare
name: Melissa Challman
role: STUDY_DIRECTOR
References:
Clinical trial NCT00860496: A Phase I Open-Label Study of the Effects of Tacrolimus and Cyclosporine on CP-690,555 in Healthy Volunteers
Official title: A Phase I, Open Label, Fixed-Sequence Study to Estimate the Effect of Tacrolimus and Cyclosporine on the Pharmacokinetics of CP-690,550 in Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy Volunteers
Keywords: Immunosuppression, JAK3 inhibitor, calcineurin inhibitors, tacrolimus, cyclosporine, pharmacokinetics, safety, tolerability
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2009-03-12
Enrollment: 24
Sex: ALL
Minimum age (years): 21
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: A new immunosuppressive drug, based on the inhibition of important enzymes in the immune system, called JAK, is being developed by Pfizer to prevent transplant rejection. Since many treatments for transplant rejection may be administered together, this research study will analyze the effects of common transplant rejection therapies, Tacrolimus and Cyclosporine, on the JAK inhibitor, CP-690,550.


Eligibility criteria: Inclusion Criteria:

* Healthy males between 21 and 55 years, inclusive.
* Healthy females of non-childbearing potential between 21 and 55 years, inclusive.
* Total body weight greater than 132 pounds.

Exclusion Criteria:

* Evidence or history of clinically significant disease
* Females of childbearing potential

Primary outcomes:
measure: Effect of multiple dose Tacrolimus and Cyclosporine on the pharmacokinetics of a single oral dose of CP-590,550 in healthy volunteers
timeFrame: 9 days
Secondary outcomes:
measure: Evaluate the safety and tolerability of a single oral dose of CP-690,550 when co-administered with Tacrolimus or Cyclosporine
timeFrame: 9 days
Other outcomes:
Locations:
city: Singapore
country: Singapore
facility: Pfizer Investigational Site
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT03738696: Liposomal Bupivacaine in Rotator Cuff Repair
Official title: Efficacy of Liposomal Bupivacaine in Arthroscopic Rotator Cuff Repair
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Rotator Cuff Injury
Lead sponsor: University of Alabama at Birmingham
Sponsor class: OTHER
Collaborators: name: Pacira Pharmaceuticals, Inc
First posted: 2018-11-13
Enrollment: 64
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To assess the efficacy of interscalene liposomal bupivacaine in controlling postoperative pain scores, oral morphine equivalents and sleep quality after arthroscopic rotator cuff repair surgery as compared to interscalene catheter.


Eligibility criteria: Inclusion Criteria:

* Undergoing outpatient arthroscopic rotator cuff repair
* Greater than or equal to 19 years of age at the time of surgery

Exclusion Criteria:

* Planned operative fixation of the biceps tendon or acromioclavicular joint
* Opioid use 6 weeks before surgery
* Gabapentin use 6 weeks before surgery
* History of prior shoulder surgery on the operative limb
* Severe pulmonary dysfunction
* Diagnosis of chronic pain, fibromyalgia or other somatosensory disorder(s)
* History of radicular pain or neuropathy in the operative limb
* Patients who are currently incapacitated for medical decision making

Primary outcomes:
measure: Average Postoperative Pain Scores Over a 96 Hour Timeframe
timeFrame: Up to 96 hrs postoperative
Secondary outcomes:
measure: Average Postoperative Oral Morphine Equivalents Over a 96 Hour Timeframe
timeFrame: Up to 96 hrs
measure: Average Analgesia Satisfaction Over a 96 Hour Timeframe
timeFrame: Up to 96 hrs
measure: Percentage of Participants With Analgesia Complications
timeFrame: Up to 96 hrs
measure: Average Sleep Quality Over a 96 Hour Timeframe
timeFrame: Up to 96 hrs postoperative
measure: Average Hours of Painless Sleep
timeFrame: Up to 96 hrs postoperative
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: UAB Hospital-Highlands
state: Alabama
Study officials:
References:
Clinical trial NCT01451996: The Efficacy of Claritin in Healthy Subjects
Official title: The Efficacy of Claritin in Healthy Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Healthy
Keywords: direct-to-consumer advertising
Lead sponsor: University of Chicago
Sponsor class: OTHER
First posted: 2011-10-14
Enrollment: 340
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The primary goal of this study is to examine determinants of the efficacy of Claritin.

Detailed description: Subjects will be given Claritin 10mg tablet. Subjects will be challenged with histamine via skin prick prior to Claritin administration and at 1 and 2 hours post administration. We will measure and record wheal and flare area 10 minutes following each challenge.

Eligibility criteria: Inclusion Criteria.

1. Males and females between 18 and 65 years of age.

Exclusion Criteria.

1. Pregnant or lactating women.
2. Upper respiratory infection within 14 days of study start.
3. Women of childbearing potential not using specific contraception method(s) (i.e., birth control pills, depo Provera, double barrier) as well as women who are breastfeeding.
4. Patients with severe medical condition(s) that in the view of the investigator prohibits participation in the study (heart, lung, kidney, neurological, oncologic or liver disease).
5. Use of any other investigational agent in the last 30 days.
6. Use of medications that may affect skin testing. Specifically, subjects are excluded if they have used an antihistamine during the 4 days preceding their treatment visit.

Primary outcomes:
measure: Change in Wheal Reaction Area From Baseline --- 2 Hour
timeFrame: baseline and 2 hours post administration of Claritin.
Secondary outcomes:
measure: Change in Wheal Reaction Area From Baseline --- 1 Hour
timeFrame: baseline and 1 hours post administration of Claritin
Other outcomes:
Locations:
city: Chicago
country: United States
facility: University of Chicago
state: Illinois
Study officials:
affiliation: University of Chicago
name: Anup Malani, J.D., Ph.D
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03951896: Efficacy of Platelet Rich Plasma Injections in Patients With Adhesive Capsulitis of the Shoulder
Official title: Efficacy of Platelet Rich Plasma Injections in Patients With Adhesive Capsulitis of the Shoulder
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Adhesive Capsulitis of Shoulder
Adhesive Capsulitis
Frozen Shoulder
Lead sponsor: Ege University
Sponsor class: OTHER
First posted: 2019-05-16
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study was done to investigate whether platelet rich plasma(PRP) injections are effective in the management of adhesive capsulitis of the shoulder(AC).Patients were randomized to 2 groups, and one group took PRP injections for 3 times every two weeks, while the other group took saline injections in same frequency and volume. A standardized exercise programme was also applied to all patients.

Patients were then evaluated with Shoulder Pain and Disability Index(SPADI), Visual analogous scales for pain and disability, Ranges of Movements and use of analgesics in before, after and 3rd month of the therapy.


Eligibility criteria: Inclusion Criteria:

* Being over 18 years old and having a shoulder pain with restriction for 3 months at least, and 9 months at most(Pain VAS being \>40 mm, and loss of ROM for affected side more than %25 of unaffected side).

Exclusion Criteria:

* Subjects were excluded if they had uncontrolled diabetes, active inflammatory diseases, ongoing pregnancy, severe anemia, psychiatric diseases that may affect compliance or cancer. Patients who had a history of trauma, recent injection therapies(\<3 months), surgery or allergy to local anaesthetics, or signs of complex regional pain syndrome, local infections or use of non steroidal anti-inflammatory drugs throughout the study were also excluded.

Primary outcomes:
measure: Shoulder Pain and Disability Index (SPADI)
timeFrame: 3 months
measure: Visual Analogous Scales for pain
timeFrame: 3 months
Secondary outcomes:
measure: Visual Analogous Scales for disability
timeFrame: 3 months
measure: Shoulder ranges of motions
timeFrame: 3 months
measure: Analgesic use
timeFrame: 3 months
Other outcomes:
Locations:
Study officials:
References: